, Volume 36, Issue 3, pp 381–382 | Cite as

Response to ‘Comment on ‘‘Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy”’

  • Amir Ansaripour
  • Carin A. Uyl-de Groot
  • W. Ken Redekop
Letter to the Editor


Compliance with Ethical Standards


No sources of funding were received for the preparation of this response.

Conflict of interest

Amir Ansaripour, Carin A. Uyl-de Groot, and W. Ken Redekop have no conflicts of interest directly relevant to the content of this response.


  1. 1.
    Ansaripour A, Uyl-de Groot C, Redekop WK. Adjuvant trastuzumab therapy for early HER2-positive breast cancer in Iran: a cost-effectiveness and scenario analysis for an optimal treatment strategy. Pharmacoeconomics. 2018;36:91–103.CrossRefPubMedGoogle Scholar
  2. 2.
    Gershon N, Berchenko Y. Optimality, future costs and terminal costs. Pharmacoeconomics. 2018.Google Scholar
  3. 3.
    Versteegh M, Knies S, Brouwer W. From good to better: new Dutch guidelines for economic evaluations in healthcare. Pharmacoeconomics. 2016;34:1071–4.CrossRefPubMedGoogle Scholar
  4. 4.
    The World Bank. In: GDP per capita (current US$). 2015. Accessed 20 Oct 2015.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Institute for Medical Technology Assessment, Erasmus School of Health Policy and ManagementErasmus University RotterdamRotterdamThe Netherlands

Personalised recommendations